Singulair is an anti-allergy drug owned by Organon. It contains the active ingredient montelukast sodium. First authorized for market use on July 26, 2002, Singulair holds a total of one patent. This patent, numbered US8007830, has already expired. Designed for oral administration, Singulair is currently available in granule dosage forms.
The Singulair generic version has the potential to be released after October 24, 2022. Although the last patent (US8007830) covering Singulair expired, the availability of Singulair generics could be delayed due to regulatory or manufacturing complexities.
Singulair is primarily used to treat and prevent asthma. The active ingredient, montelukast sodium, works by blocking the action of certain natural substances that cause swelling in the lungs and constriction of the airways. This helps to decrease the symptoms of asthma and prevent asthma attacks.
The patent that most significantly affects the availability of Singulair generic forms is US8007830, which expired, paving the way for a potential release of generics after October 24, 2022. Below are the details of the patent: